Endovascular thrombectomy has fundamentally transformed the management of acute ischemic stroke caused by large vessel occlusion. However, clinical uncertainty persists regarding the absolute utility of bridging intravenous thrombolysis prior to endovascular therapy. Specifically, clinicians frequently debate whether administering IV thrombolysis before thrombectomy provides additive clinical value or merely increases bleeding risk when procedural delays occur. A comprehensive multicenter study now provides robust real-world evidence confirming that bridging thrombolysis delivers time-independent clinical benefits without elevating procedural hazards.

Evolving Paradigms in IV Thrombolysis Before Thrombectomy

Historically, intravenous tissue plasminogen activator served as the solitary proven medical reperfusion therapy for acute ischemic stroke. The advent of mechanical thrombectomy subsequently redefined standard care for emergent anterior circulation large vessel occlusions. However, direct mechanical intervention sparked widespread debate regarding whether pre-treatment thrombolytic infusions remain necessary.

Proponents of direct thrombectomy argue that avoiding systemic fibrinolytics decreases symptomatic intracranial hemorrhage risk. Furthermore, skipping thrombolysis might expedite groin puncture in comprehensive stroke facilities. In contrast, advocates of bridging therapy highlight several distinct pathophysiological advantages. Systemic thrombolysis dissolves microvascular thrombi and enhances collateral microcirculation downstream of the main occlusion. In addition, biochemical clot softening frequently facilitates smoother mechanical extraction during catheterization. Consequently, bridging therapy could secure partial recanalization while transfer teams mobilize patients. Recent randomized clinical trials examined this dilemma, yet their strict selection criteria left substantial real-world uncertainties. Therefore, large international registries remain crucial to clarify how intravenous thrombolytics perform across heterogeneous emergency presentation windows.

STAR Cohort Analysis and Study Design

To resolve these questions, investigators evaluated data from the Stroke Thrombectomy and Aneurysm Registry. This rigorous study aggregated acute ischemic stroke patients treated across 46 international stroke centers between 2016 and 2025. Specifically, the cohort included 7,118 adult patients who presented with anterior circulation large vessel occlusion. Researchers categorized subjects into two primary groups based on elapsed time from symptom onset to arrival at the thrombectomy facility.

Patients who arrived within 4.5 hours formed the early-thrombectomy cohort. In contrast, individuals who presented after 4.5 hours constituted the late-thrombectomy cohort. The research team further bifurcated both timing cohorts based on whether patients received prior intravenous thrombolysis. Investigators meticulously adjusted for confounding variables using multiple multivariable logistic regression models and formal interaction testing. Moreover, researchers implemented propensity score matching to generate well-balanced comparative groups. The primary efficacy endpoint centered on ninety-day functional independence, defined as a modified Rankin Scale score of 0 to 2. Accordingly, secondary endpoints tracked successful angiographic recanalization, unintended embolization into new vascular territories, and symptomatic intracranial hemorrhage.

Functional Independence and Recanalization Outcomes

The registry findings demonstrated compelling functional improvements among patients who received pre-treatment thrombolytic therapy. Across the entire cohort of 7,118 patients, intravenous thrombolysis independently predicted functional independence at ninety days with an adjusted odds ratio of 1.40. Expectedly, presentation beyond 4.5 hours independently correlated with poorer functional recovery, showing an adjusted odds ratio of 0.56.

Importantly, formal interaction testing revealed no significant interaction between intravenous thrombolysis and the thrombectomy presentation window. This critical statistical finding confirms that the beneficial impact of thrombolytic administration persisted regardless of procedural timing. Furthermore, stratified multivariable analyses reinforced this conclusion across individual presentation intervals. Among early-thrombectomy patients, bridging therapy significantly improved the odds of achieving functional independence, yielding an adjusted odds ratio of 1.56. Similarly, patients in the late-thrombectomy group derived substantial benefits from prior thrombolysis, achieving an adjusted odds ratio of 1.27. In addition, bridging therapy maintained high rates of successful angiographic recanalization without increasing distal clot fragmentation. Consequently, these robust data confirm that intravenous thrombolysis actively supports endovascular efficacy throughout extended time frames.

Safety Profiles and Hemorrhagic Risk Assessment

Safety concerns, particularly the risk of symptomatic intracranial hemorrhage, frequently discourage clinicians from combining pharmacologic and mechanical reperfusion. However, analysis of this large international registry showed no measurable safety penalties associated with bridging thrombolysis. Rates of symptomatic intracranial hemorrhage remained statistically comparable between patients receiving bridging therapy and those undergoing direct thrombectomy alone.

Moreover, the propensity-matched analysis provided even stronger safety reassurances. Within the matched cohort of 1,022 bridging patients, early-thrombectomy patients demonstrated superior ninety-day functional independence compared to late-thrombectomy patients. Nevertheless, investigators detected no significant differences in symptomatic intracranial hemorrhage rates between the early and late groups. Similarly, thrombolytic pre-treatment did not increase the incidence of clot migration or embolization into previously unaffected arterial branches. These safety outcomes directly counter common fears that systemic thrombolysis might destabilize thrombi or weaken ischemic microvasculature during extended transfers. Therefore, clinicians can confidently administer indicated intravenous fibrinolytics without dreading elevated catastrophic hemorrhage rates. Ultimately, the cumulative safety profile firmly supports aggressive dual-modality reperfusion pathways.

Implications for Drip-and-Ship Stroke Networks

These findings carry profound implications for regional stroke systems, particularly those operating decentralized drip-and-ship care models. In many healthcare environments, including acute stroke networks across India, patients initially present to community facilities lacking endovascular capabilities. Consequently, inter-hospital transfer to comprehensive endovascular centers often introduces unavoidable logistical delays exceeding the classical therapeutic window.

Historically, physicians worried that administering thrombolytic drugs before prolonged transport might provide little benefit while compounding procedural risks upon destination arrival. The current data strongly refute this assumption. Specifically, bridging thrombolysis preserved significant clinical advantages even when mechanical groin puncture occurred well beyond 4.5 hours from onset. Thrombolysis maintains microvascular patency during prolonged ambulance transit, effectively shielding salvageable ischemic penumbra against progressive necrosis. Furthermore, initiating early chemical recanalization prevents secondary clot propagation along collateral vessels. Stroke systems should therefore reinforce protocols ensuring rapid intravenous thrombolytic infusion at primary spoke hospitals. Clinicians must immediately transfer eligible patients for catheter angiography without waiting to observe post-thrombolysis clinical changes. Accordingly, eliminating treatment hesitations will optimize neurological recovery across complex transfer networks.

Frequently Asked Questions

Does bridging thrombolysis increase bleeding risk during late thrombectomy?

No. Robust registry data show that pre-treatment with intravenous thrombolysis does not significantly increase symptomatic intracranial hemorrhage or distal embolization. These favorable safety profiles persist even when endovascular thrombectomy occurs beyond the standard 4.5-hour onset window, confirming that bridging therapy remains safe across diverse transfer timeframes.

Why does intravenous thrombolysis benefit patients undergoing delayed mechanical thrombectomy?

Intravenous thrombolysis dissolves microthrombi and preserves downstream capillary perfusion within the ischemic penumbra while patients await catheterization. Furthermore, biochemical enzymatic action softens the primary arterial occlusion. Consequently, neurointerventionalists can achieve faster, more complete mechanical recanalization, improving ninety-day functional independence regardless of baseline transportation delays.

How should transfer stroke networks structure protocols for large vessel occlusions?

Emergency networks should implement immediate drip-and-ship protocols. Community spoke centers must administer indicated intravenous thrombolytic therapy without delay and instantly dispatch the patient to a comprehensive endovascular thrombectomy facility. Clinicians should never delay inter-hospital transport to monitor post-infusion clinical progress, as rapid dual-modality treatment yields optimal recovery.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. The operational guidelines mentioned may vary across regions and healthcare settings. Refer to the latest local and national guidelines for clinical practice.

References

1. Chacon A et al. Time-independent value of IV thrombolysis in stroke thrombectomy: Evidence from a multicenter cohort. Clin Neurol Neurosurg. 2026 Nov. doi: 10.1016/j.clineuro.2026.109572. PMID: 42508138.
2. Turc G, Bhogal P, Fischer U, et al. European Stroke Organisation (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) Guidelines on Mechanical Thrombectomy in Acute Ischaemic Stroke. J Neurointerv Surg. 2019;11(6):535-538.
3. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723-1731.